Boosting tarlatamab effectiveness for small cell lung cancer
A Novel Approach to Enhance Therapeutic Efficacy of Tarlatamab for Small Cell Lung Cancer Treatment
Researchers are trying ways to boost how well the DLL3-targeting drug tarlatamab fights small cell lung cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11269230 on NIH RePORTER |
What this research studies
This project aims to find molecular factors that make small cell lung cancer cells more or less sensitive to tarlatamab, a DLL3-targeting T-cell engager. The team will use CRISPR-based gene activation in laboratory tumor cells to turn on candidate genes and test whether that changes immune cell killing. Experiments will include cell line work and preclinical models to identify targets that could be combined with tarlatamab or used as predictive biomarkers. Promising findings would be used to design future clinical trials to try to extend patient responses.
Who could benefit from this research
Good fit: Ideal candidates are people with relapsed or previously treated small cell lung cancer who have DLL3-positive tumors and who might receive tarlatamab in current or future clinical trials.
Not a fit: Patients whose tumors lack DLL3 expression or who are too frail for immunotherapy are unlikely to benefit from tarlatamab-based approaches.
Why it matters
Potential benefit: If successful, this work could lead to combinations or biomarkers that help patients get longer, stronger responses to tarlatamab.
How similar studies have performed: Tarlatamab has already produced objective responses in prior clinical trials, but using CRISPR activation to boost its effect is an experimental and largely novel approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Wajapeyee, Narendra — University of Alabama at Birmingham
- Study coordinator: Wajapeyee, Narendra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.